Rye Brook Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rye Brook Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-23,100	Closed	-$3.13M	–	29
2021 Q1	$3.13M	Buy	23,100 +4,900	+27%	+$734K	2.28%	16
2020 Q4	$2.56M	Buy	+18,200	New	+$2.33M	2.23%	16

Other funds holding XBI

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Rye Brook Capital's XBI Position: Q2 2021 in Review

Rye Brook Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2021, closing a stake of 23,100 shares — an estimated $3.13M sold.

Rye Brook Capital first reported a position in XBI in Q4 2020 and held it in 2 quarters. The position peaked at $3.13M in Q1 2021. 663 funds tracked by Wall St. Rank hold XBI as of Q2 2021.

Rye Brook Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2021 after selling out during the quarter.
Rye Brook Capital sold 23,100 State Street SPDR S&P Biotech ETF shares in Q2 2021, an estimated $3.13M.
Rye Brook Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 2 quarters.
Rye Brook Capital's State Street SPDR S&P Biotech ETF position peaked at $3.13M in Q1 2021.
663 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2021.

Based on Rye Brook Capital's 13F filing for Q2 2021, filed 19 Jul 2021.